skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension

Original Research

(2661) Views  (607) Full article downloads

Authors: Bernard Waeber, Jean-Jacques Mourad

Published Date May 2008 Volume 2008:4(1) Pages 249 - 252
DOI: http://dx.doi.org/10.2147/VHRM.S2598

Bernard Waeber1, Jean-Jacques Mourad2

1Division de Physiopathologie Clinique, Centre Hospitalier Universitaire Vaudois et Université de Lausanne, Lausanne, Switzerland; 2Hôpital Avicienne, Bobigny, France

Abstract: A score system integrating the evolution of efficacy and tolerability over time was applied to a subpopulation of the STRATHE trial, a trial performed according to a parallel group design, with a double-blind, random allocation to either a fixed-dose combination strategy (perindopril/indapamide 2 mg/0.625 mg, with the possibility to increase the dose to 3 mg/0.935 mg, and 4 mg/1.250 mg if needed, n = 118), a sequential monotherapy approach (atenolol 50 mg, followed by losartan 50 mg and amlodipine 5 mg if needed, n = 108), or a stepped-care strategy (valsartan 40 mg, followed by valsartan 80 mg and valsartan 80 mg+ hydrochlorothiazide 12.5 mg if needed, n = 103). The aim was to lower blood pressure below 140/90 mmHg within a 9-month period. The treatment could be adjusted after 3 and 6 months. Only patients in whom the study protocol was strictly applied were included in this analysis. At completion of the trial the total score averaged 13.1 ± 70.5 (mean ± SD) using the fixed-dose combination strategy, compared with –7.2 ± 81.0 using the sequential monotherapy approach and –17.5 ± 76.4 using the stepped-care strategy. In conclusion, the use of a score system allows the comparison of antihypertensive therapeutic strategies, taking into account at the same time efficacy and tolerability. In the STRATHE trial the best results were observed with the fixed-dose combination containing low doses of an angiotensin enzyme converting inhibitor (perindopril) and a diuretic (indapamide).

Keywords: antihypertensive therapy, tolerability, antihypertensive efficacy, fixed-dose combination, sequential monotherapy, stepped-care treatment






 

Other articles by Professor Bernard Waeber



Readers of this article also read:

Prevalence and component analysis of metabolic syndrome: An Indian atherosclerosis research study perspective
Endothelial effects of antihypertensive treatment: focus on irbesartan
Effect of short-term lycopene supplementation and postprandial dyslipidemia on plasma antioxidants and biomarkers of endothelial health in young, healthy individuals
Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Comparative assessment of angiotensin receptor blockers in different clinical settings
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Diagnostic accuracy of dual-source CT angiography and coronary risk stratification
Long-term use and tolerability of irbesartan for control of hypertension
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University